Brief: Immunocore And Gadeta Announce Agreement To Develop First Gamma Delta (Γδ) Tcr Immtac For Solid Tumors

Immunocore Holdings

02/12/2022 12:35

Dec 2 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE AND GADETA ANNOUNCE AGREEMENT TO DEVELOP FIRST
GAMMA
DELTA (ΓΔ) TCR IMMTAC FOR SOLID TUMORS
    * IMMUNOCORE HOLDINGS PLC - CO HAS AN OPTION FOR EXCLUSIVE
LICENSE
TO FURTHER RESEARCH, DEVELOP AND COMMERCIALIZE IMMTAC CANDIDATES
FROM COLLABORATION
    * IMMUNOCORE HOLDINGS PLC - UNDER TERMS OF AGREEMENT,
IMMUNOCORE
AND GADETA WILL COLLABORATE ON '201 ΓΔ-TCR TARGET DISCOVERY
    * IMMUNOCORE HOLDINGS- UNDER TERMS OF AGREEMENT, CO TO HAVE
OPTION
TO DEVELOP IMMTAC THERAPIES DERIVED FROM '201 TCR AS PART OF
RESEARCH COLLABORATION

Source text for Eikon:  ID:nGNX2fZH6c 
Further company coverage:  IMCR.O 
 ((Reuters.Briefs@thomsonreuters.com;;))